Want to see PRME full AI Analyst Report?
PRME Stock Chart & Stats
$2.95
$0.15(5.08%)
At close: 4:00 PM EDT
$2.95
$0.15(5.08%)
Day’s Range― - ―
52-Week Range$2.67 - $6.94
Previous CloseN/A
Volume304.95K
Average Volume (3M)3.83M
Market Cap
$553.20M
Enterprise Value$671.37
Total Cash (Recent Filing)$95.07M
Total Debt (Recent Filing)$112.48M
Price to Earnings (P/E)―
Beta2.88
Next Earnings
Oct 30, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding181,376,860
10 Day Avg. Volume3,073,602
30 Day Avg. Volume3,829,343
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)4.27
Price to Sales (P/S)111.44
P/FCF Ratio-3.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.83Price Target Upside165.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$9.33M
Bulls Say, Bears Say
Bulls Say
Pipeline And Clinical ProgressMultiple programs are progressing toward clinical or regulatory milestones, while human CGD data supports the platform’s therapeutic potential. Continued advancement could diversify future value beyond a single asset, although development risk remains high.
Clearer PM647 Development RightsThe favorable arbitration outcome clarifies Prime’s rights to develop PM647 and removes a significant legal uncertainty. This supports continuity of the AATD program and reduces the risk that collaboration disputes disrupt development or commercialization plans.
Governance StabilityShareholder approval of directors and the independent auditor indicates continuity in oversight during a capital-intensive development period. Stable governance can support consistent execution, accountability, and investor confidence as clinical programs advance.
Bears Say
Persistent Operating LossesVery limited and declining revenue cannot currently offset research and development costs, leaving the company dependent on external financing. Persistent losses also make future profitability highly reliant on successful clinical, regulatory, and commercial execution.
Significant Cash BurnSustained cash consumption indicates ongoing funding needs before products can generate meaningful commercial revenue. Continued burn may require additional capital, potentially limiting strategic flexibility and creating financing or dilution risk over the next several quarters.
Weakening Balance SheetHigher leverage alongside rapid equity erosion reduces financial resilience and the capacity to absorb clinical setbacks. A weaker equity cushion may make future funding more consequential and increase dependence on favorable development outcomes.
Prime Medicine, Inc. News
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $2.67 and its highest was $6.94 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $553.20M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is Oct 30, 2026 which is in 71 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.257 by $0.017.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. pays a Quarterly dividend of $0.006 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 181,376,860 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.257. Following the earnings report the stock price went down -4.221%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prime Medicine, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.83 (165.54% Upside)
$7.83 (165.54% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 780.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.74%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
PRME Stock 12 Month Forecast
Average Price Target
$7.83
▲(165.54% Upside)
Technical Analysis
Immatics
―
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
13.25% Insiders
7.21% Mutual Funds
27.79% Other Institutional Investors
37.28% Public Companies and
Individual Investors